Chemotherapy(paclitaxel)-induced Polyneuropathy in Breast Cancer As Part of the REBECCA Project (REsearch on BrEast Cancer Induced Chronic Conditions Supported by Causal Analysis of Multi-source Data)
This is a single center prospective observational cohort study that aims to: * examine and identify possible risk and susceptibility factors for the incidence and progression of chemotherapy-induced polyneuropathy (CIPN) in female patients primarily operated for early non-metastatic breast cancer who will receive adjuvant chemotherapy containing paclitaxel * test different neurophysiological methods for early detection of CIPN * explore changes that underlie the development of CIPN in relation to clinical presentations, neurophysiological assessment, including measures of small nerve fiber dysfunction, and possible biochemical, metabolic and genetic associations * explore the effects of CIPN in the patient's lifestyle and quality of life for up to 12 months after the initiation of treatment
• Female patients
• Age of ≥ 18 years
• Newly operated primary breast cancer without metastatic disease receiving adjuvant chemotherapy containing paclitaxel
• No prior chemotherapy other than cyclophosphamide and epirubicin
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
• Written informed consent
• Able to communicate with investigators, participate in testing and comply with the requirements of the study-protocol